Test Price
2,800 AED✅ Home Collection Available
TNFAIP3 Gene (Rheumatoid Arthritis Susceptibility) Next‑Generation Sequencing DNA Test in UAE | 2,800 AED
Executive Summary & Core Metrics
Clinically validated NGS analysis of the TNFAIP3 coding region for rheumatoid arthritis susceptibility profiling with 99.9% diagnostic sensitivity.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Certified Next‑Generation Sequencing (NGS) with Illumina® platform at 100x coverage.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary post‑test telephonic result interpretation with a board‑certified genetic counsellor.
- Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The TNFAIP3 gene encodes the A20 protein, a central negative regulator of NF‑κB signalling. Loss‑of‑function variants in this gene are strongly associated with increased susceptibility to rheumatoid arthritis (RA), psoriatic arthritis, and systemic autoimmune disorders. This next‑generation sequencing assay comprehensively analyses all coding exons and flanking splice regions (±20 bp) of TNFAIP3, enabling detection of single nucleotide variants and small insertions/deletions linked to RA risk. Results empower early diagnosis, prognostic stratification, and targeted therapeutic decisions along the IL‑17/NF‑κB axis.
| Feature | Our Test (NGS) | Standard PCR Panel |
|---|---|---|
| Methodology | High‑throughput NGS (Illumina® platform, 100x coverage) | Targeted Sanger sequencing (few hotspots) |
| Coverage | Full TNFAIP3 coding exons ±20 bp splice regions | Limited to 2–3 common SNPs |
| Turnaround Time | 21–28 Business Days | 4 to 6 Weeks |
| Clinical Grade | ISO 9001:2015 Certified, DHA‑licensed facility | Generic lab accreditation |
| Pre‑test Genetic Counseling | Included (mandatory session) | Often not offered |
Physician Insight & Safety Protocols
“A genetic finding of a TNFAIP3 variant indicates elevated susceptibility, not a guaranteed diagnosis. The result must be integrated with the patient’s rheumatologic history, joint examination findings, serological markers, and family pedigree. My advice is to review every detected variant with the referring rheumatologist before initiating or altering any therapy. This test is a decision‑support tool, not a standalone diagnostic.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notice
⚠️ Important Clinical Caution
Never stop or change prescribed immunosuppressive or biologic therapy based solely on a genetic test result. Always consult your treating physician for medication adjustments. Genetic risk information is intended to inform, not override, your current treatment plan.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active systemic infection, recent blood transfusion (less than 2 weeks), or inability to provide informed consent. Minors require legal guardian presence per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Exclusion: Pregnancy is not a contraindication, but special venipuncture precautions apply.
- Emergency Red Flags: Sudden severe joint swelling accompanied by fever, new‑onset vasculitic rash, or acute eye pain (suspected uveitis) — seek immediate emergency care rather than genetic testing.
- Paediatric Requirement: A legal guardian must accompany all minors during sample collection in accordance with UAE medical liability regulations.
Patient FAQ & Clinical Guidance
1. What is the TNFAIP3 gene and how does it influence rheumatoid arthritis risk?
Answer: The TNFAIP3 gene provides instructions for producing the A20 protein, a key brake on NF‑κB‑driven inflammation. Pathogenic variants that impair A20 function remove this brake, leading to excessive inflammatory signalling and heightened susceptibility to rheumatoid arthritis and related autoimmune conditions. Our NGS test identifies such variants across the entire coding region.
2. How accurate is the TNFAIP3 NGS test for detecting pathogenic variants?
Answer: The assay delivers greater than 99.9% analytical sensitivity for single nucleotide variants and small indels within the TNFAIP3 coding exons and splice junctions. Variant interpretation follows ACMG/AMP guidelines, and each finding is correlated with your rheumatologic profile to produce a clinically actionable risk assessment.
3. Is pre‑test genetic counselling mandatory before proceeding?
Answer: Yes, a complimentary pre‑test counselling session is mandatory. Our board‑certified genetic counsellor will document a detailed family pedigree, explain possible outcomes, and discuss the psychosocial implications of your results. This ensures fully informed consent before sample collection.
4. What sample types are accepted for this genetic analysis?
Answer: We accept whole blood collected in EDTA tubes, previously extracted DNA, or a single dried blood spot on an FTA card. Buccal swabs are not validated for this high‑sensitivity NGS assay because they cannot guarantee the required genomic DNA yield and integrity. Our temperature‑controlled courier service handles all collections.
UAE Regulatory & Data Privacy Adherence
This laboratory service operates in full compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the collection, processing, and storage of your genetic and health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — regulating electronic health records and telemedicine interactions.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability — ensuring patient consent, safety, and clinical accountability throughout the testing pathway.
Your genetic data is encrypted, stored on UAE‑based servers, and never shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | TNFAIP3 Gene (Rheumatoid Arthritis Susceptibility) NGS DNA Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Business Days |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina® Platform, 100x Coverage |
| ICD‑10‑CM Code | M05.9, L40.59, Z15.09 |
| LOINC Code | 69787-6 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians